LGALS3BP Antibody

LGALS3BP Antibody CATALOG NUMBER: 26-926 Antibody used in WB on Human Brain at 0.2-1 ug/ml. Specifications SPECIES REACTIVITY: Human, Mouse TESTED APPLICATIONS: ELISA, WB APPLICATIONS: LGALS3BP antibody can be used for detection of LGALS3BP by ELISA at 1:312500. LGALS3BP antibody can be used for detection of LGALS3BP by western blot at 1 ug/mL, and HRP conjugated secondary antibody should be diluted 1:50,000 - 100,000. USER NOTE: Optimal dilutions for each application to be determined by the researcher. POSITIVE CONTROL: 1) Cat. No. XBL-10123 - Fetal Brain Tissue Lysate PREDICTED MOLECULAR 63 kDa WEIGHT: IMMUNOGEN: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human LGALS3BP. HOST SPECIES: Rabbit Properties PURIFICATION: Antibody is purified by peptide affinity chromatography method. PHYSICAL STATE: Lyophilized BUFFER: Antibody is lyophilized in PBS buffer with 2% sucrose. Add 50 uL of distilled water. Final antibody concentration is 1 mg/mL. CONCENTRATION: 1 mg/ml STORAGE CONDITIONS: For short periods of storage (days) store at 4˚C. For longer periods of storage, store LGALS3BP antibody at - 20˚C. As with any antibody avoid repeat freeze-thaw cycles. CLONALITY: Polyclonal CONJUGATE: Unconjugated Additional Info ALTERNATE NAMES: LGALS3BP, 90K, MAC-2-BP, BTBD17B, TANGO10B ACCESSION NO.: NP_005558 PROTEIN GI NO.: 5031863 OFFICIAL SYMBOL: LGALS3BP GENE ID: 3959 Background BACKGROUND: The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. LGALS3BP has been found elevated in the serum of patients with cancer and in those infected by the human immunodeficiency virus (HIV). It appears to be implicated in immune response associated with natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity. The native protein binds specifically to a human macrophage-associated lectin known as Mac-2 and also binds galectin 1.The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. LGALS3BP has been found elevated in the serum of patients with cancer and in those infected by the human immunodeficiency virus (HIV). It appears to be implicated in immune response associated with natural killer (NK) and lymphokine- activated killer (LAK) cell cytotoxicity. Using fluorescence in situ hybridization the full length 90K cDNA has been localized to chromosome 17q25. The native protein binds specifically to a human macrophage-associated lectin known as Mac-2 and also binds galectin 1. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications. REFERENCES: 1) Lee, Y.J., Clin. Exp. Rheumatol. 25 (4 SUPPL 45), S41-S45 (2007). FOR RESEARCH USE ONLY December 12, 2016.

Copy Link

Recommended publications

Datasheet A02938-1 Anti-LGALS3BP Antibody
Product datasheet Anti-LGALS3BP Antibody Catalog Number: A02938-1 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Basic Information Product Name Anti-LGALS3BP Antibody Gene Name LGALS3BP Source Rabbit IgG Species Reactivity human,mouse Tested Application WB,IHC-P Contents 500ug/ml antibody with PBS ，0.02% NaN3 , 1mg BSA and 50% glycerol. Immunogen A synthetic peptide corresponding to a sequence of human LGALS3BP (HEALFQKKTLQALEFHTVPFQLLARYKGLNLTEDTYKPR). Purification Immunogen affinity purified. Observed MW 65KD Dilution Ratios Western blot: 1:500-2000 Immunohistochemistry in paraffin section: 1:50-400 (Boiling the paraffin sections in 10mM citrate buffer,pH6.0,or PH8.0 EDTA repair liquid for 20 mins is required for the staining of formalin/paraffin sections.) Optimal working dilutions must be determined by end user. Storage 12 months from date of receipt，-20℃ as supplied.6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing Background Information Galectin-3-binding protein is a protein that in humans is encoded by the LGALS3BP gene. The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. LGALS3BP has been found elevated in the serum of patients with cancer and in those infected by the human immunodeficiency virus (HIV). It appears to be implicated in immune response associated with natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity. Using fluorescence in situ hybridization the full length 90K cDNA has been localized to chromosome 17q25.
[Show full text]
Pancreatic Cancer Invasion of the Lymphatic Vasculature and Contributions of the Tumor Microenvironment: Roles for E- Selectin and CXCR4
University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Fall 12-16-2016 Pancreatic Cancer Invasion of the Lymphatic Vasculature and Contributions of the Tumor Microenvironment: Roles for E- selectin and CXCR4 Maria M. Steele University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Recommended Citation Steele, Maria M., "Pancreatic Cancer Invasion of the Lymphatic Vasculature and Contributions of the Tumor Microenvironment: Roles for E-selectin and CXCR4" (2016). Theses & Dissertations. 166. https://digitalcommons.unmc.edu/etd/166 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. i PANCREATIC CANCER INVASION OF THE LYMPHATIC VASCULATURE AND CONTRIBUTIONS OF THE TUMOR MICROENVIRONMENT: ROLES FOR E-SELECTIN AND CXCR4 By Maria M. Steele A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Cancer Research Graduate Program Under the Supervision of Professor Michael A. Hollingsworth University of Nebraska Medical Center Omaha, NE November, 2016 Supervisory Committee Michael A. Hollingsworth, Ph.D. Kaustubh Datta, Ph.D. Angie Rizzino, Ph.D. Joyce C. Solheim, Ph.D. ii PANCREATIC CANCER INVASION OF THE LYMPHATIC VASCULATURE AND CONTRIBUTIONS OF THE TUMOR MICROENVIRONMENT: ROLES FOR E-SELECTIN AND CXCR4 Maria M. Steele University of Nebraska, 2016 Advisor: Michael A. Hollingsworth ABSTRACT As the fourth leading cause of cancer-related deaths, pancreatic cancer is one of the most lethal forms of cancers in the United States.
[Show full text]
King's Research Portal
King’s Research Portal DOI: 10.3892/ijo.2016.3521 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Woodman, N., Pinder, S. E., Tajadura, V., Le Bourhis, X., Gillett, C., Delannoy, P., Burchell, J. M., & Julien, S. (2016). Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer. International Journal of Oncology, 49(1), 265-275. https://doi.org/10.3892/ijo.2016.3521 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
[Show full text]
LGALS3BP Rabbit Pab
Leader in Biomolecular Solutions for Life Science LGALS3BP Rabbit pAb Catalog No.: A12005 Basic Information Background Catalog No. The galectins are a family of beta-galactoside-binding proteins implicated in A12005 modulating cell-cell and cell-matrix interactions. LGALS3BP has been found elevated in the serum of patients with cancer and in those infected by the human immunodeficiency Observed MW virus (HIV). It appears to be implicated in immune response associated with natural killer 70kDa (NK) and lymphokine-activated killer (LAK) cell cytotoxicity. Using fluorescence in situ hybridization the full length 90K cDNA has been localized to chromosome 17q25. The Calculated MW native protein binds specifically to a human macrophage-associated lectin known as 65kDa Mac-2 and also binds galectin 1. Category Primary antibody Applications WB Cross-Reactivity Human, Mouse Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 3959 Q08380 Immunogen Recombinant fusion protein containing a sequence corresponding to amino acids 6-221 of human LGALS3BP (NP_005558.1). Synonyms LGALS3BP;90K;BTBD17B;CyCAP;M2BP;MAC-2-BP;TANGO10B;gp90 Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using LGALS3BP antibody (A12005) at 1:3000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 90s.
[Show full text]
Human Lectins, Their Carbohydrate Affinities and Where to Find Them
biomolecules Review Human Lectins, Their Carbohydrate Affinities and Where to Review HumanFind Them Lectins, Their Carbohydrate Afﬁnities and Where to FindCláudia ThemD. Raposo 1,*, André B. Canelas 2 and M. Teresa Barros 1 1, 2 1 Cláudia D. Raposo * , Andr1 é LAQVB. Canelas‐Requimte,and Department M. Teresa of Chemistry, Barros NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829‐516 Caparica, Portugal; [email protected] 12 GlanbiaLAQV-Requimte,‐AgriChemWhey, Department Lisheen of Chemistry, Mine, Killoran, NOVA Moyne, School E41 of ScienceR622 Co. and Tipperary, Technology, Ireland; canelas‐ [email protected] NOVA de Lisboa, 2829-516 Caparica, Portugal; [email protected] 2* Correspondence:Glanbia-AgriChemWhey, [email protected]; Lisheen Mine, Tel.: Killoran, +351‐212948550 Moyne, E41 R622 Tipperary, Ireland; [email protected] * Correspondence: [email protected]; Tel.: +351-212948550 Abstract: Lectins are a class of proteins responsible for several biological roles such as cell‐cell in‐ Abstract:teractions,Lectins signaling are pathways, a class of and proteins several responsible innate immune for several responses biological against roles pathogens. such as Since cell-cell lec‐ interactions,tins are able signalingto bind to pathways, carbohydrates, and several they can innate be a immuneviable target responses for targeted against drug pathogens. delivery Since sys‐ lectinstems. In are fact, able several to bind lectins to carbohydrates, were approved they by canFood be and a viable Drug targetAdministration for targeted for drugthat purpose. delivery systems.Information In fact, about several specific lectins carbohydrate were approved recognition by Food by andlectin Drug receptors Administration was gathered for that herein, purpose. plus Informationthe specific organs about speciﬁc where those carbohydrate lectins can recognition be found by within lectin the receptors human was body.
[Show full text]
Supplementary Material Contents
Supplementary Material Contents Immune modulating proteins identified from exosomal samples.....................................................................2 Figure S1: Overlap between exosomal and soluble proteomes.................................................................................... 4 Bacterial strains:..............................................................................................................................................4 Figure S2: Variability between subjects of effects of exosomes on BL21-lux growth.................................................... 5 Figure S3: Early effects of exosomes on growth of BL21 E. coli .................................................................................... 5 Figure S4: Exosomal Lysis............................................................................................................................................ 6 Figure S5: Effect of pH on exosomal action.................................................................................................................. 7 Figure S6: Effect of exosomes on growth of UPEC (pH = 6.5) suspended in exosome-depleted urine supernatant ....... 8 Effective exosomal concentration....................................................................................................................8 Figure S7: Sample constitution for luminometry experiments..................................................................................... 8 Figure S8: Determining effective concentration .........................................................................................................
[Show full text]
Deciphering the Molecular Profile of Plaques, Memory Decline And
ORIGINAL RESEARCH ARTICLE published: 16 April 2014 AGING NEUROSCIENCE doi: 10.3389/fnagi.2014.00075 Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer’s disease by deep sequencing Yvonne Bouter 1†,Tim Kacprowski 2,3†, Robert Weissmann4, Katharina Dietrich1, Henning Borgers 1, Andreas Brauß1, Christian Sperling 4, Oliver Wirths 1, Mario Albrecht 2,5, Lars R. Jensen4, Andreas W. Kuss 4* andThomas A. Bayer 1* 1 Division of Molecular Psychiatry, Georg-August-University Goettingen, University Medicine Goettingen, Goettingen, Germany 2 Department of Bioinformatics, Institute of Biometrics and Medical Informatics, University Medicine Greifswald, Greifswald, Germany 3 Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany 4 Human Molecular Genetics, Department for Human Genetics of the Institute for Genetics and Functional Genomics, Institute for Human Genetics, University Medicine Greifswald, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany 5 Institute for Knowledge Discovery, Graz University of Technology, Graz, Austria Edited by: One of the central research questions on the etiology of Alzheimer’s disease (AD) is the Isidro Ferrer, University of Barcelona, elucidation of the molecular signatures triggered by the amyloid cascade of pathological Spain events. Next-generation sequencing allows the identification of genes involved in disease Reviewed by: Isidro Ferrer, University of Barcelona, processes in an unbiased manner. We have combined this technique with the analysis of Spain two AD mouse models: (1) The 5XFAD model develops early plaque formation, intraneu- Dietmar R. Thal, University of Ulm, ronal Ab aggregation, neuron loss, and behavioral deficits. (2)TheTg4–42 model expresses Germany N-truncated Ab4–42 and develops neuron loss and behavioral deficits albeit without plaque *Correspondence: formation.
[Show full text]
LGALS3BP Mouse Monoclonal Antibody [Clone ID: OTI1C2] Product Data
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for CF503456 LGALS3BP Mouse Monoclonal Antibody [Clone ID: OTI1C2] Product data: Product Type: Primary Antibodies Clone Name: OTI1C2 Applications: FC, IF, WB Recommended Dilution: WB 1:2000, IF 1:100, FLOW 1:100 Reactivity: Human Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Human recombinant protein fragment corresponding to amino acids 19-300 of human LGALS3BP(NP_005558) produced in E.coli. Formulation: Lyophilized powder (original buffer 1X PBS, pH 7.3, 8% trehalose) Reconstitution Method: For reconstitution, we recommend adding 100uL distilled water to a final antibody concentration of about 1 mg/mL. To use this carrier-free antibody for conjugation experiment, we strongly recommend performing another round of desalting process. (OriGene recommends Zeba Spin Desalting Columns, 7KMWCO from Thermo Scientific) Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 65.2 kDa Gene Name: Homo sapiens galectin 3 binding protein (LGALS3BP), mRNA. Database Link: NP_005558 Entrez Gene 3959 Human Q08380 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 LGALS3BP Mouse Monoclonal Antibody [Clone ID: OTI1C2] – CF503456 Background: The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell- cell and cell-matrix interactions.
[Show full text]
The N-Terminal Domain of the Spike Protein As Another Emerging Target for Hampering the SARS-Cov-2 Attachment to Host Cells
International Journal of Molecular Sciences Perspective More Is Always Better Than One: The N-Terminal Domain of the Spike Protein as Another Emerging Target for Hampering the SARS-CoV-2 Attachment to Host Cells Sonia Di Gaetano 1,2,† , Domenica Capasso 2,3,† , Pietro Delre 4,5, Luciano Pirone 1 , Michele Saviano 2,4, Emilia Pedone 1,2,* and Giuseppe Felice Mangiatordi 4 1 Institute of Biostructures and Bioimaging, CNR, 80134 Naples, Italy; [email protected] (S.D.G.); [email protected] (L.P.) 2 CIRPEB, University of Naples “Federico II”, 80134 Naples, Italy; [email protected] (D.C.); [email protected] (M.S.) 3 CESTEV, University of Naples “Federico II”, 80145 Naples, Italy 4 Institute of Crystallography, CNR, 70126 Bari, Italy; [email protected] (P.D.); [email protected] (G.F.M.) 5 Chemistry Department, University of Bari, 70121 Bari, Italy * Correspondence: [email protected]; Tel.: +39-081-253-4521 † The authors contribute equally to this work. Abstract: Although the approved vaccines are proving to be of utmost importance in containing the Coronavirus disease 2019 (COVID-19) threat, they will hardly be resolutive as new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, a single-stranded RNA virus) variants might be Citation: Di Gaetano, S.; Capasso, D.; insensitive to the immune response they induce. In this scenario, developing an effective therapy is Delre, P.; Pirone, L.; Saviano, M.; still a dire need. Different targets for therapeutic antibodies and diagnostics have been identiﬁed, Pedone, E.; Mangiatordi, G.F. More Is among which the SARS-CoV-2 spike (S) glycoprotein, particularly its receptor-binding domain, has Always Better Than One: The been deﬁned as crucial.
[Show full text]
LGALS3BP Mouse Monoclonal Antibody [Clone ID: OTI1C2] Product Data
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA503456 LGALS3BP Mouse Monoclonal Antibody [Clone ID: OTI1C2] Product data: Product Type: Primary Antibodies Clone Name: OTI1C2 Applications: FC, IF, WB Recommended Dilution: WB 1:2000, IF 1:100, FLOW 1:100 Reactivity: Human Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Human recombinant protein fragment corresponding to amino acids 19-300 of human LGALS3BP(NP_005558) produced in E.coli. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 1 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 65.2 kDa Gene Name: galectin 3 binding protein Database Link: NP_005558 Entrez Gene 3959 Human Q08380 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 LGALS3BP Mouse Monoclonal Antibody [Clone ID: OTI1C2] – TA503456 Background: The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell- cell and cell-matrix interactions. LGALS3BP has been found elevated in the serum of patients with cancer and in those infected by the human immunodeficiency virus (HIV). It appears to be implicated in immune response associated with natural killer (NK) and lymphokine- activated killer (LAK) cell cytotoxicity.
[Show full text]
GSE50161, (C) GSE66354, (D) GSE74195 and (E) GSE86574
Figure S1. Boxplots of normalized samples in five datasets. (A) GSE25604, (B) GSE50161, (C) GSE66354, (D) GSE74195 and (E) GSE86574. The x‑axes indicate samples, and the y‑axes represent the expression of genes. Figure S2. Volanco plots of DEGs in five datasets. (A) GSE25604, (B) GSE50161, (C) GSE66354, (D) GSE74195 and (E) GSE86574. Red nodes represent upregulated DEGs and green nodes indicate downregulated DEGs. Cut‑off criteria were P<0.05 and |log2 FC|>1. DEGs, differentially expressed genes; FC, fold change; adj.P.Val, adjusted P‑value. Figure S3. Transcription factor‑gene regulatory network constructed using the Cytoscape iRegulion plug‑in. Table SI. Primer sequences for reverse transcription‑quantitative polymerase chain reaction. Genes Sequences hsa‑miR‑124 F: 5'‑ACACTCCAGCTGGGCAGCAGCAATTCATGTTT‑3' R: 5'‑CTCAACTGGTGTCGTGGA‑3' hsa‑miR‑330‑3p F: 5'‑CATGAATTCACTCTCCCCGTTTCTCCCTCTGC‑3' R: 5'‑CCTGCGGCCGCGAGCCGCCCTGTTTGTCTGAG‑3' hsa‑miR‑34a‑5p F: 5'‑TGGCAGTGTCTTAGCTGGTTGT‑3' R: 5'‑GCGAGCACAGAATTAATACGAC‑3' hsa‑miR‑449a F: 5'‑TGCGGTGGCAGTGTATTGTTAGC‑3' R: 5'‑CCAGTGCAGGGTCCGAGGT‑3' CD44 F: 5'‑CGGACACCATGGACAAGTTT‑3' R: 5'‑TGTCAATCCAGTTTCAGCATCA‑3' PCNA F: 5'‑GAACTGGTTCATTCATCTCTATGG‑3' F: 5'‑TGTCACAGACAAGTAATGTCGATAAA‑3' SYT1 F: 5'‑CAATAGCCATAGTCGCAGTCCT‑3' R: 5'‑TGTCAATCCAGTTTCAGCATCA‑3' U6 F: 5'‑GCTTCGGCAGCACATATACTAAAAT‑3' R: 5'‑CGCTTCACGAATTTGCGTGTCAT‑3' GAPDH F: 5'‑GGAAAGCTGTGGCGTGAT‑3' R: 5'‑AAGGTGGAAGAATGGGAGTT‑3' hsa, homo sapiens; miR, microRNA; CD44, CD44 molecule (Indian blood group); PCNA, proliferating cell nuclear antigen;
[Show full text]
The GALNT6‑LGALS3BP Axis Promotes Breast Cancer Cell Growth
INTERNATIONAL JOURNAL OF ONCOLOGY 56: 581-595, 2020 The GALNT6‑LGALS3BP axis promotes breast cancer cell growth RYUICHIRO KIMURA1,8*, TETSURO YOSHIMARU1,2*, YOSUKE MATSUSHITA1,2*, TAISUKE MATSUO1, MASAYA ONO3, JAE‑HYUN PARK4, MITSUNORI SASA5, YASUO MIYOSHI6, YUSUKE NAKAMURA7 and TOYOMASA KATAGIRI1,2 1Division of Genome Medicine, Institute of Advanced Medical Sciences; 2Research Cluster on Integrated Cancer Drug Discovery, Tokushima University, Tokushima, Tokushima 770-8503; 3Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo 104-0045; 4Cancer Precision Medicine, Inc., Kawasaki, Kanagawa 210‑0821; 5Department of Surgery, Tokushima Breast Care Clinic, Tokushima, Tokushima 770-0052; 6Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501; 7Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan Received May 20, 2019; Accepted October 24, 2019 DOI: 10.3892/ijo.2019.4941 Abstract. Polypeptide N-acetylgalactosaminyltransferase 6 and S582A) in cells drastically reduced GALNT6-dependent (GALNT6), which is involved in the initiation of O-glycosylation, LGALS3BP O-glycosylation and secretion, resulting in suppres- has been reported to play crucial roles in mammary carcinogen- sion of autocrine growth-promoting effect. The findings of esis through binding to several substrates; however, its biological the present study suggest that the GALNT6-LGALS3BP axis roles in mediating growth-promoting effects remain unknown. is crucial for breast cancer cell proliferation and may be a The present study demonstrated a crucial pathophysiological therapeutic target and biomarker for mammary tumors. role of GALNT6 through its O-glycosylation of lectin galacto- side-binding soluble 3 binding protein (LGALS3BP), a secreted Introduction growth-promoting glycoprotein, in breast cancer growth.
[Show full text]